OPTIMI HEALTH CORP - OPTHF STOCK NEWS

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) secures CAD $1,000,000 from Catcher Investments Ltd. for a non-dilutive Debt Financing Agreement and General Security Agreement. The financing will bear interest at 7.5% per annum and mature on August 4, 2026. The company also granted 100,000 common share purchase warrants to Mr. JJ Wilson, its director and non-executive Chair.

Optimi Health Corp. has successfully completed its proprietary natural psilocybin extraction process under GMP. The process increases potency while maintaining the mushroom's botanical characteristics, reducing production costs and opening new possibilities. Optimi is the only publicly listed Canadian manufacturer focused on GMP-grade psychedelics. The company has filed a U.S. provisional patent application to protect its extraction process.

Optimi Health Corp. has entered into a CAD$1.2 million supply agreement with a private entity focused on mushroom-based therapeutic drugs. The company will cultivate dried GMP psilocybin-containing biomass and extract for distribution to international research sites.

Optimi Health Corp. (OTCQX: OPTHF) has announced a significant long-term distribution agreement with Mind Medicine Australia to supply GMP-grade MDMA and psilocybin for therapeutic use in Australia. This follows the Australian government's reclassification allowing authorized psychiatrists to prescribe these substances for treatment-resistant conditions starting July 1, 2023. Key aspects include signed purchase orders for medical-grade substances manufactured under GMP protocols at Optimi's Health Canada licensed facility. This agreement represents Optimi's first international sales of these products, supporting the push for expanded access to psychedelic therapies in response to the mental health crisis.

Optimi Health Corp. has submitted a clinical trial application for a Phase I study to evaluate the safety of its natural psilocybin standardized extract and proprietary MDMA drug candidate in healthy therapists. This trial, conducted in collaboration with ATMA Journey Centers, is the first to compare the effects of both substances. The study aims to enroll 25 participants across five groups, assessing safety and physiological markers. The company aims to address the significant shortage of therapists trained in psychedelic therapy as it progresses towards commercialization.